Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Pancreatic Function Tests”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1979

Improved diagnostic accuracy of a modified oral pancreatic function test.

The oral pancreatic function test (PFT) depends upon urinary recovery of p-aminobenzoic acid (PABA) released by chymotrypsin hydrolysis of orally administered N-benzoyl-L-tyrosyl-p-aminobenzoid acid. The diagnostic value of the test is limited because falsely abnormal results frequently occur in patients with bowel or liver disease in whom PABA recovery is impaired by abnormal absorption or hepatic conjugation, even though pancreatic function is normal. To overcome this problem, we have modified the oral PFT to correct for impaired PABA absorption and conjugation. Results of the oral PFT have been compared with urinary recovery of an equivalent dose of free PABA in order to derive a PABA excretion index (PEI). When the modified oral PFT is used, the PEI clearly distinguished patients with pancreatic disease from normal subjects. In patients with small-bowel or liver disease and normal exocrine pancreatic function, the PEI results were similar to those of normal subjects, although a previous oral PFT had been falsey abnormal. The modified test can therefore distinguish abnormal results due to pancreatic disease from the falsely abnormal results found in liver and small-bowel disease.

4-Aminobenzoic Acid↗
PubMed1979

The diagnostic value of the oral pancreatic function test.

An oral pancreatic function test (PFT) using the synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid can assess pancreatic exocrine function, since urinary recovery of the ingested dose is an indirect index of chymotryptic activity. We have studied 34 subjects using this oral PFT, which correctly distinguished the control group (8 subjects) from the pancreatitis group (10 patients), results correlating well with Lundh test findings. However, the test was falsely abnormal on 9 out of 16 occasions in patients with bowel or liver disease. We therefore conclude that the present test cannot distinguish small-bowel disease from pancreatic disease, which is often the diagnostic problem, and is also frequently falsely abnormal in the presence of chronic liver disease.

4-Aminobenzoic Acid↗
PubMed1976

Continuous secretin infusion with pancreozymin pretreatment as a pancreatic function test.

This paper deals with a pancreatic function test with the submaximal dose of secretin given by continuous infusion after injection of cholecystokinin-pancreozymin (CCK-PZ) in the submaximal dose. The active elimination of bladder bile by CCK-PZ pretreatment decreased the influence of biliary contamination, and the volume output and the bicarbonate concentration were stabilized by the continuous infusion of secretin. As a result, the coefficients of variation in the volume output and the bicarbonate concentration were calculated to be about 15 and about 5%, respectively. These variations were considerably smaller than those obtained in the standard secretin test. Therefore, the present study is expected to improve the diagnostic means for pancreatic excretory dysfunction.

Amylases↗
PubMed1979

[Modern pancreatic function tests].

The functional diagnostics is a corner-pillar of the difficult diagnostics of pancreas. Despite new tests many wishes remain open. The secretine-pancreozymine test and the Lundh-test give good informations, but they are expensive and for the patients considerably stressing. They certainly are not regarded as screening tests. The suitable and justifiable tests for epidemiologic examinations (estimations of stool enzymes and of serum isoamylase) are less specific and sensitive. A differentiation between chronic pancreatitis and neoplasm of the pancreas is not possible with the help of the functional diagnostics. The results of functional examinations may be correctly evaluated only within all informations which concentrate at the patient's bed.

4-Aminobenzoic Acid↗
PubMed1979

Improved sensitivity of the BTPABA pancreatic function test in animals with meals of raw egg white.

An indirect exocrine pancreatic function test (PFT) which measures the ability of a test to hydrolyze a chymotrypsin-labile peptide (N-benzoyl-L-tyrosyl-PABA), was carried out in rats and swine with simulated partial exocrine pancreatic insufficiency. When spray-dried egg white (SDEW), which contains an inhibitor of chymotrypsin, was administered as a test meal with the PFT, the degree of pancreatic insufficiency was more pronounced. The results suggest that SDEW or raw egg while may be useful as a test meal to be given in conjunction with the PFT in humans in order to accentuate moderate degrees of pancreatic insufficiency and improve the sensitivity of this indirect test of pancreatic function.

4-Aminobenzoic Acid↗
PubMed1978

Plasma cyclic AMP levels during a secretin-caerulein pancreatic function test in liver and pancreatic disease.

Plasma cyclic AMP levels were determined during a 40 minute secretin infusion (1 Cl.U kg-1h-1) followed by a 40 minute combined secretin (1 Cl.U kg-1h-1) caerulein (75 ng kg-1h-1) infusion. In nine healthy subjects, both secretin alone and secretin in combination with caerulein did not affect plasma cyclic AMP levels. The same was observed in six patients with chronic pancreatitis. By contrast, in patients suffering from liver disease (nine cases) or extrahepatic cholestasis (six cases), secretin elicited large increases in plasma cyclic AMP concentration; the mean values attained being, respectively, seven and four times higher than before the infusion. On the other hand, increases in plasma cyclic AMP 10 minutes after a bolus injection of glucagon (1 mg) were four times lower in the liver disease group as compared to the controls. The results reported here suggest that the liver plays a major role in the degradation of plasma cyclic AMP produced by target tissues responding to secretin, and in the release of cyclic AMP under glucagon. Liver disease reduce the capacity of the liver to clear cyclic AMP from the blood. The pancreas does not contribute significantly to the cyclic AMP in the blood.

Ceruletide↗
PubMed1975

[Computer-aided diagnosis for pancreatic function test (author's transl)].

The use of multivariate nonlinear discriminant analysis raised the rate of correct classification for 585 pancreatic function tests from 84 percent by the doctor to 93 percent by computer analysis. In addition to the "normal" and "pancreatic" disease groups, a group of 388 patients was found in whom secretion levels were neither normal nor typical of pancreatic disease. For this group, nonpancreatic gastroenterologic disease was established with a diagnostic accuracy of 98 percent. Representation of secretion data by Andrews' method for the differentiation of pancreatitis from carcinoma allows moderately sensitive but highly specific testing.

Cholecystokinin↗
PubMed1979

Exocrine pancreatic function test by a synthetic peptide.

A new synthetic substance, N-Benzoyl-L-tyrosyl-p-aminobenzoic acid, is specially cleaved by pancreatic chymotrypsin after oral administration and the released p-aminobenzoic acid (P.A.B.A.) is absorbed and excreted in the urine. The P.A.B.A. recovery in the urine was examined to evaluate its diagnostic value as an exocrine pancreatic function test. The data permit the following conclusions: 1. There is a significant correlation between this test and maximal bicarbonate concentration, amylase output and volume of P.Z./C.C.K. secretin test. 2. More than one-half to two-thirds proximal or one-third distal of the pancreas must be removed before one can expect an abnormal result in this test. 3. This is a simple and useful test to detect exocrine pancreatic insufficiency of more than moderate degree but normal results may be obtained in minimal to mild exocrine pancreatic insufficiency. Only six of 11 cases (54.5%) with one abnormal factor of P-S test showed decreased P.A.B.A. recpvery, whereas 22 of 23 cases (95.7%) with two or three abnormal factors of P-S test showed decreased or borderline P.A.B.A. recovery.

4-Aminobenzoic Acid↗
PubMed1976

[Methodological and first clinical investigations using a new pancreatic function test].

The synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid was tested in vitro and in vivo for its chymotrypsin specificity. Comparative kinetic tests with bovine chymotrypsin and human pancreatic juice, as well as clearance tests with p-aminobenzoic acid (PABA), made this peptide seem suitable for an indirect pancreatic-function test. A testing scheme was set up for clinical use which has yielded promising preliminary results. While in 31 out of 32 healthy subjects there were normal PABA excretion rates in the urine collected over six hours, the test correlated well in 15 out of 16 cases of definite pancreatic disorder. The percentage dose excretion of PABA in the urine collected over six hours gave good correlations with the one-hour amount of chymotrypsin in the pancreozymin-secretin-test and with the concentration of chymotrypsin in the feces. These preliminary results make this test appear an appropriate screening method for pancreatopathy.

Aminobenzoates↗
PubMed1978

[Biochemistry and clinical significance of oral exocrine pancreatic function test by means of fluoresceinedilaurate (author's transl)].

Column chromatography of extracts and secretions of the pancreas as well as of sera from patients suffering from inflammations of this organ yields three esterases different from each other in molecular size. These enzymes could be shown to be not identical with lipase. They may be classified as aryl-esterases considering their activities in hydrolyzing synthetic substrates such as esters of fluoresceine with fatty acids. Fluoresceinedilaurate, therefore, proved to be very advantageous in an orally performed test of exocrine pancreatic function. Healthy persons show in this procedure relative excretion of fluoresceine during ten hours of 66.3 +/- 30.4%, patients suffering from pancreatic diseases only 12.7 +/- 9.8% of the dye.

Esterases↗